

Special Issue

Vector-Borne Diseases in a COVID-19 Redesigned World

Message from the Guest Editor

More than simply supplanting any other health topic on the list of public health concerns, SARS-CoV-2 has been completely redesigning the present and future of Vector-Borne Diseases (VBD). The COVID-19 situation may provide new insights into VBD prevention, surveillance, and diagnostics, as well as a higher acceptability of innovative solutions, such as RNA vaccines, Point-Of-Care molecular methods to detect RNA viruses, mobile-based tracing of infected cases, biological surveillance of travelers, to name a few. Such innovative strategies implemented with the hope of quickly winning the battle against COVID-19 might become durable solutions to prevent and manage VBD outbreaks; however, such innovative solutions are often expensive and impractical, thus increasing the gap between high- and low-income countries. For this reason, low-cost strategies for VBD surveillance and vector-control in low-resources settings are of great importance.

Guest Editor

Dr. Van-Mai Cao-Lormeau

Institut Louis Malardé, Po Box 30, 98 713 Papeete, Tahiti, French Polynesia, France

Deadline for manuscript submissions

closed (22 December 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/78824

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).